Egypt

Egypt

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
1.96 (1.56 - 2.43) 2015 Modelled WHO
1 (0.90 - 1.20) 2016 Modelled Razavi-Shearer et al, 2018
1.71 (1.67 - 1.76) 2013 Modelled Schweitzer et al, 2015
1.4 (1.20 - 1.60) 2015 Survey/reported Ismail et al, 2017
1 2015 Survey/reported Ministry of Health et al, 2015
1 2019 Modelled Global Burden of Disease Study 2019
3.61 (3.43 - 3.84) 2019 Modelled IHME, GBD 2019 (accessed 2020)
4.1 (3.89 - 4.34) 2018 Modelled IHME, GBD 2019 (accessed 2022)
4.16 (3.90 - 4.43) 2017 Modelled IHME, GBD 2019 (accessed 2022)
4.3 (4.06 - 4.54) 2016 Modelled IHME, GBD 2019 (accessed 2022)
4.4 (4.16 - 4.69) 2015 Modelled IHME, GBD 2019 (accessed 2022)
4.45 (4.22 - 4.72) 2014 Modelled IHME, GBD 2019 (accessed 2022)
4.57 (4.32 - 4.82) 2013 Modelled IHME, GBD 2019 (accessed 2022)
4.71 (4.45 - 4.97) 2012 Modelled IHME, GBD 2019 (accessed 2022)
4.84 (4.54 - 5.11) 2011 Modelled IHME, GBD 2019 (accessed 2022)
4.9 (4.57 - 5.22) 2010 Modelled IHME, GBD 2019 (accessed 2022)
4.94 (4.63 - 5.26) 2009 Modelled IHME, GBD 2019 (accessed 2022)
5.03 (4.73 - 5.35) 2008 Modelled IHME, GBD 2019 (accessed 2022)
5.13 (4.84 - 5.46) 2007 Modelled IHME, GBD 2019 (accessed 2022)
5.22 (4.93 - 5.56) 2006 Modelled IHME, GBD 2019 (accessed 2022)
5.27 (4.96 - 5.62) 2005 Modelled IHME, GBD 2019 (accessed 2022)
5.31 (5 - 5.65) 2004 Modelled IHME, GBD 2019 (accessed 2022)
5.4 (5.12 - 5.74) 2003 Modelled IHME, GBD 2019 (accessed 2022)
5.51 (5.22 - 5.85) 2002 Modelled IHME, GBD 2019 (accessed 2022)
5.6 (5.29 - 5.95) 2001 Modelled IHME, GBD 2019 (accessed 2022)
5.64 (5.30 - 6.01) 2000 Modelled IHME, GBD 2019 (accessed 2022)
5.66 (5.34 - 6.03) 1999 Modelled IHME, GBD 2019 (accessed 2022)
5.72 (5.39 - 6.08) 1998 Modelled IHME, GBD 2019 (accessed 2022)
5.78 (5.43 - 6.16) 1997 Modelled IHME, GBD 2019 (accessed 2022)
5.84 (5.48 - 6.23) 1996 Modelled IHME, GBD 2019 (accessed 2022)
5.87 (5.49 - 6.26) 1995 Modelled IHME, GBD 2019 (accessed 2022)
5.88 (5.51 - 6.26) 1994 Modelled IHME, GBD 2019 (accessed 2022)
5.9 (5.53 - 6.29) 1993 Modelled IHME, GBD 2019 (accessed 2022)
5.95 (5.55 - 6.34) 1992 Modelled IHME, GBD 2019 (accessed 2022)
6 (5.58 - 6.40) 1991 Modelled IHME, GBD 2019 (accessed 2022)
6.06 (5.60 - 6.48) 1990 Modelled IHME, GBD 2019 (accessed 2022)
4.05 (3.84 - 4.30) 2019 Modelled IHME, GBD 2019 (accessed 2022)
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.8 (0.54 - 1.10) 2015 Modelled WHO
0.11 (0.09 - 0.13) 2019 Modelled IHME, GBD 2019 (accessed 2020)
0.14 (0.11 - 0.16) 2019 Modelled IHME, GBD 2019 (accessed 2022)
0.15 (0.12 - 0.18) 2018 Modelled IHME, GBD 2019 (accessed 2022)
0.15 (0.12 - 0.19) 2017 Modelled IHME, GBD 2019 (accessed 2022)
0.16 (0.13 - 0.19) 2016 Modelled IHME, GBD 2019 (accessed 2022)
0.15 (0.13 - 0.19) 2015 Modelled IHME, GBD 2019 (accessed 2022)
0.15 (0.13 - 0.19) 2014 Modelled IHME, GBD 2019 (accessed 2022)
0.15 (0.12 - 0.18) 2013 Modelled IHME, GBD 2019 (accessed 2022)
0.15 (0.12 - 0.18) 2012 Modelled IHME, GBD 2019 (accessed 2022)
0.15 (0.12 - 0.18) 2011 Modelled IHME, GBD 2019 (accessed 2022)
0.15 (0.12 - 0.18) 2010 Modelled IHME, GBD 2019 (accessed 2022)
0.15 (0.12 - 0.19) 2009 Modelled IHME, GBD 2019 (accessed 2022)
0.16 (0.13 - 0.19) 2008 Modelled IHME, GBD 2019 (accessed 2022)
0.17 (0.14 - 0.21) 2007 Modelled IHME, GBD 2019 (accessed 2022)
0.19 (0.15 - 0.22) 2006 Modelled IHME, GBD 2019 (accessed 2022)
0.2 (0.16 - 0.24) 2005 Modelled IHME, GBD 2019 (accessed 2022)
0.22 (0.18 - 0.27) 2004 Modelled IHME, GBD 2019 (accessed 2022)
0.26 (0.21 - 0.31) 2003 Modelled IHME, GBD 2019 (accessed 2022)
0.29 (0.24 - 0.35) 2002 Modelled IHME, GBD 2019 (accessed 2022)
0.33 (0.27 - 0.40) 2001 Modelled IHME, GBD 2019 (accessed 2022)
0.36 (0.29 - 0.44) 2000 Modelled IHME, GBD 2019 (accessed 2022)
0.39 (0.31 - 0.47) 1999 Modelled IHME, GBD 2019 (accessed 2022)
0.41 (0.33 - 0.49) 1998 Modelled IHME, GBD 2019 (accessed 2022)
0.42 (0.34 - 0.52) 1997 Modelled IHME, GBD 2019 (accessed 2022)
0.45 (0.36 - 0.55) 1996 Modelled IHME, GBD 2019 (accessed 2022)
0.49 (0.39 - 0.60) 1995 Modelled IHME, GBD 2019 (accessed 2022)
0.6 (0.48 - 0.74) 1994 Modelled IHME, GBD 2019 (accessed 2022)
0.83 (0.66 - 1.01) 1993 Modelled IHME, GBD 2019 (accessed 2022)
1.13 (0.91 - 1.39) 1992 Modelled IHME, GBD 2019 (accessed 2022)
1.5 (1.21 - 1.84) 1991 Modelled IHME, GBD 2019 (accessed 2022)
1.9 (1.52 - 2.33) 1990 Modelled IHME, GBD 2019 (accessed 2022)
0.2 (0.17 - 0.24) 2020 Modelled WHO
Showing out of
Show more
Technical notes

Number of people living with chronic HBV

National
Download
Value Year Type Source
996,000 (884,000 - 1,116,000) 2016 Modelled Razavi-Shearer et al, 2018
3,578,980 (3,393,270 - 3,800,360) 2019 Modelled IHME, GBD 2019 (accessed 2020)
3,800,740 (3,607,580 - 4,038,170) 2019 Modelled IHME, GBD 2019 (accessed 2022)
3,786,750 (3,595,670 - 4,003,770) 2018 Modelled IHME, GBD 2019 (accessed 2022)
3,786,610 (3,547,340 - 4,022,880) 2017 Modelled IHME, GBD 2019 (accessed 2022)
3,846,450 (3,637,030 - 4,068,660) 2016 Modelled IHME, GBD 2019 (accessed 2022)
3,875,730 (3,658,370 - 4,124,640) 2015 Modelled IHME, GBD 2019 (accessed 2022)
3,850,580 (3,654,000 - 4,078,720) 2014 Modelled IHME, GBD 2019 (accessed 2022)
3,879,060 (3,675,980 - 4,091,460) 2013 Modelled IHME, GBD 2019 (accessed 2022)
3,924,830 (3,706,230 - 4,142,960) 2012 Modelled IHME, GBD 2019 (accessed 2022)
3,950,980 (3,711,290 - 4,179,030) 2011 Modelled IHME, GBD 2019 (accessed 2022)
3,919,650 (3,660,910 - 4,175,690) 2010 Modelled IHME, GBD 2019 (accessed 2022)
3,874,290 (3,630,890 - 4,119,530) 2009 Modelled IHME, GBD 2019 (accessed 2022)
3,865,580 (3,638,600 - 4,104,580) 2008 Modelled IHME, GBD 2019 (accessed 2022)
3,868,140 (3,650,380 - 4,102,310) 2007 Modelled IHME, GBD 2019 (accessed 2022)
3,857,750 (3,635,380 - 4,096,470) 2006 Modelled IHME, GBD 2019 (accessed 2022)
3,809,100 (3,588,980 - 4,055,820) 2005 Modelled IHME, GBD 2019 (accessed 2022)
3,757,870 (3,551,460 - 3,994,610) 2004 Modelled IHME, GBD 2019 (accessed 2022)
3,741,010 (3,544,290 - 3,968,480) 2003 Modelled IHME, GBD 2019 (accessed 2022)
3,734,810 (3,537,940 - 3,964,270) 2002 Modelled IHME, GBD 2019 (accessed 2022)
3,716,830 (3,512,320 - 3,947,860) 2001 Modelled IHME, GBD 2019 (accessed 2022)
3,664,960 (3,449,780 - 3,904,540) 2000 Modelled IHME, GBD 2019 (accessed 2022)
3,606,300 (3,398,590 - 3,836,320) 1999 Modelled IHME, GBD 2019 (accessed 2022)
3,571,980 (3,367,460 - 3,805,890) 1998 Modelled IHME, GBD 2019 (accessed 2022)
3,546,800 (3,336,130 - 3,775,290) 1997 Modelled IHME, GBD 2019 (accessed 2022)
3,516,600 (3,294,870 - 3,749,970) 1996 Modelled IHME, GBD 2019 (accessed 2022)
3,467,000 (3,240,390 - 3,708,720) 1995 Modelled IHME, GBD 2019 (accessed 2022)
3,409,200 (3,196,620 - 3,635,930) 1994 Modelled IHME, GBD 2019 (accessed 2022)
3,361,610 (3,143,870 - 3,580,970) 1993 Modelled IHME, GBD 2019 (accessed 2022)
3,321,110 (3,101,940 - 3,536,440) 1992 Modelled IHME, GBD 2019 (accessed 2022)
3,286,180 (3,056,150 - 3,502,160) 1991 Modelled IHME, GBD 2019 (accessed 2022)
3,254,630 (3,003,040 - 3,479,980) 1990 Modelled IHME, GBD 2019 (accessed 2022)
Showing out of
Show more

HBV-related death rate

National
Download
Value (per 100,000) Year Type Source
19.4 (11.80 - 28.70) 2019 Modelled IHME, GBD 2019 (accessed 2020)
31.51 (24.46 - 41.63) 1990 Modelled IHME, GBD 2019 (accessed 2022)
30.46 (23.66 - 39.77) 1991 Modelled IHME, GBD 2019 (accessed 2022)
29.51 (23.05 - 38.30) 1992 Modelled IHME, GBD 2019 (accessed 2022)
29.31 (22.91 - 37.88) 1993 Modelled IHME, GBD 2019 (accessed 2022)
29.08 (22.70 - 37.79) 1994 Modelled IHME, GBD 2019 (accessed 2022)
28.24 (22.01 - 36.51) 1995 Modelled IHME, GBD 2019 (accessed 2022)
27.79 (21.59 - 35.96) 1996 Modelled IHME, GBD 2019 (accessed 2022)
27.76 (21.66 - 36.12) 1997 Modelled IHME, GBD 2019 (accessed 2022)
27.41 (21.22 - 35.86) 1999 Modelled IHME, GBD 2019 (accessed 2022)
27.58 (21.42 - 36.15) 1998 Modelled IHME, GBD 2019 (accessed 2022)
26.61 (20.47 - 34.86) 2000 Modelled IHME, GBD 2019 (accessed 2022)
26.76 (20.65 - 35.26) 2001 Modelled IHME, GBD 2019 (accessed 2022)
25.89 (19.72 - 34.36) 2002 Modelled IHME, GBD 2019 (accessed 2022)
24.71 (18.51 - 33.22) 2003 Modelled IHME, GBD 2019 (accessed 2022)
20.65 (15.13 - 28.20) 2006 Modelled IHME, GBD 2019 (accessed 2022)
22.77 (16.78 - 31.03) 2004 Modelled IHME, GBD 2019 (accessed 2022)
21.3 (15.59 - 29.08) 2005 Modelled IHME, GBD 2019 (accessed 2022)
20.12 (14.72 - 27.55) 2007 Modelled IHME, GBD 2019 (accessed 2022)
20.09 (14.53 - 27.61) 2008 Modelled IHME, GBD 2019 (accessed 2022)
20.25 (14.51 - 27.97) 2009 Modelled IHME, GBD 2019 (accessed 2022)
20.08 (14.24 - 27.71) 2010 Modelled IHME, GBD 2019 (accessed 2022)
19.91 (14.04 - 27.57) 2011 Modelled IHME, GBD 2019 (accessed 2022)
19.88 (13.91 - 27.40) 2012 Modelled IHME, GBD 2019 (accessed 2022)
19.22 (13.47 - 26.25) 2013 Modelled IHME, GBD 2019 (accessed 2022)
19.15 (13.30 - 26.43) 2014 Modelled IHME, GBD 2019 (accessed 2022)
19.47 (13.22 - 27.21) 2015 Modelled IHME, GBD 2019 (accessed 2022)
19.53 (13.05 - 27.53) 2016 Modelled IHME, GBD 2019 (accessed 2022)
19.34 (12.34 - 27.82) 2017 Modelled IHME, GBD 2019 (accessed 2022)
19.37 (11.77 - 28.65) 2019 Modelled IHME, GBD 2019 (accessed 2022)
19.35 (12.13 - 28.25) 2018 Modelled IHME, GBD 2019 (accessed 2022)
Showing out of
Show more
Technical notes

HBV-related deaths

National
Download
Value Year Type Source
6,621 2016 Modelled WHO
17,552 (13,623 - 23,187) 1990 Modelled IHME, GBD 2019 (accessed 2022)
17,308 (13,440 - 22,596) 1991 Modelled IHME, GBD 2019 (accessed 2022)
17,094 (13,351 - 22,188) 1992 Modelled IHME, GBD 2019 (accessed 2022)
17,303 (13,526 - 22,362) 1993 Modelled IHME, GBD 2019 (accessed 2022)
17,492 (13,655 - 22,733) 1994 Modelled IHME, GBD 2019 (accessed 2022)
17,304 (13,487 - 22,373) 1995 Modelled IHME, GBD 2019 (accessed 2022)
17,357 (13,485 - 22,461) 1996 Modelled IHME, GBD 2019 (accessed 2022)
17,676 (13,793 - 23,003) 1997 Modelled IHME, GBD 2019 (accessed 2022)
17,913 (13,914 - 23,486) 1998 Modelled IHME, GBD 2019 (accessed 2022)
18,170 (14,071 - 23,772) 1999 Modelled IHME, GBD 2019 (accessed 2022)
18,012 (13,856 - 23,596) 2000 Modelled IHME, GBD 2019 (accessed 2022)
18,504 (14,275 - 24,377) 2001 Modelled IHME, GBD 2019 (accessed 2022)
18,284 (13,924 - 24,261) 2002 Modelled IHME, GBD 2019 (accessed 2022)
16,774 (12,362 - 22,856) 2004 Modelled IHME, GBD 2019 (accessed 2022)
17,822 (13,350 - 23,959) 2003 Modelled IHME, GBD 2019 (accessed 2022)
15,879 (11,637 - 21,683) 2006 Modelled IHME, GBD 2019 (accessed 2022)
15,813 (11,566 - 21,645) 2007 Modelled IHME, GBD 2019 (accessed 2022)
16,027 (11,732 - 21,886) 2005 Modelled IHME, GBD 2019 (accessed 2022)
16,132 (11,663 - 22,166) 2008 Modelled IHME, GBD 2019 (accessed 2022)
16,614 (11,901 - 22,942) 2009 Modelled IHME, GBD 2019 (accessed 2022)
16,824 (11,929 - 23,211) 2010 Modelled IHME, GBD 2019 (accessed 2022)
17,033 (12,006 - 23,585) 2011 Modelled IHME, GBD 2019 (accessed 2022)
17,127 (12,002 - 23,391) 2013 Modelled IHME, GBD 2019 (accessed 2022)
17,362 (12,144 - 23,928) 2012 Modelled IHME, GBD 2019 (accessed 2022)
18,024 (12,239 - 25,187) 2015 Modelled IHME, GBD 2019 (accessed 2022)
17,398 (12,084 - 24,013) 2014 Modelled IHME, GBD 2019 (accessed 2022)
18,406 (12,296 - 25,947) 2016 Modelled IHME, GBD 2019 (accessed 2022)
18,543 (11,837 - 26,676) 2017 Modelled IHME, GBD 2019 (accessed 2022)
18,860 (11,828 - 27,543) 2018 Modelled IHME, GBD 2019 (accessed 2022)
19,190 (11,665 - 28,385) 2019 Modelled IHME, GBD 2019 (accessed 2022)
19,190 (11,665 - 28,385) 2019 Modelled IHME, GBD 2019 (accessed 2020)
Showing out of
Show more
Technical notes

Percent of cases of hepatocellular carcinoma attributable to HBV

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
16 (11 - 24) 1990 Modelled IHME, GBD 2019 (accessed 2022)
17 (12 - 25) 1991 Modelled IHME, GBD 2019 (accessed 2022)
18 (12 - 26) 1992 Modelled IHME, GBD 2019 (accessed 2022)
18 (13 - 26) 1993 Modelled IHME, GBD 2019 (accessed 2022)
19 (13 - 27) 1994 Modelled IHME, GBD 2019 (accessed 2022)
20 (13 - 28) 1995 Modelled IHME, GBD 2019 (accessed 2022)
20 (14 - 29) 1996 Modelled IHME, GBD 2019 (accessed 2022)
21 (14 - 29) 1997 Modelled IHME, GBD 2019 (accessed 2022)
21 (14 - 29) 1998 Modelled IHME, GBD 2019 (accessed 2022)
21 (15 - 29) 1999 Modelled IHME, GBD 2019 (accessed 2022)
21 (15 - 30) 2000 Modelled IHME, GBD 2019 (accessed 2022)
22 (15 - 32) 2001 Modelled IHME, GBD 2019 (accessed 2022)
23 (16 - 32) 2002 Modelled IHME, GBD 2019 (accessed 2022)
24 (16 - 34) 2004 Modelled IHME, GBD 2019 (accessed 2022)
23 (16 - 32) 2003 Modelled IHME, GBD 2019 (accessed 2022)
27 (19 - 39) 2007 Modelled IHME, GBD 2019 (accessed 2022)
26 (18 - 38) 2006 Modelled IHME, GBD 2019 (accessed 2022)
25 (17 - 36) 2005 Modelled IHME, GBD 2019 (accessed 2022)
28 (20 - 40) 2008 Modelled IHME, GBD 2019 (accessed 2022)
31 (21 - 45) 2009 Modelled IHME, GBD 2019 (accessed 2022)
31 (21 - 45) 2010 Modelled IHME, GBD 2019 (accessed 2022)
31 (21 - 46) 2011 Modelled IHME, GBD 2019 (accessed 2022)
31 (21 - 46) 2013 Modelled IHME, GBD 2019 (accessed 2022)
31 (20 - 46) 2012 Modelled IHME, GBD 2019 (accessed 2022)
30 (20 - 46) 2015 Modelled IHME, GBD 2019 (accessed 2022)
31 (20 - 46) 2014 Modelled IHME, GBD 2019 (accessed 2022)
32 (20 - 48) 2017 Modelled IHME, GBD 2019 (accessed 2022)
31 (20 - 47) 2016 Modelled IHME, GBD 2019 (accessed 2022)
32 (20 - 48) 2018 Modelled IHME, GBD 2019 (accessed 2022)
32 (20 - 49) 2019 Modelled IHME, GBD 2019 (accessed 2022)
13 (9 - 19) 2019 Modelled IHME, GBD 2019 (accessed 2020)
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
91 2019 Survey/reported WHO/UNICEF
89 2018 Survey/reported WHO/UNICEF
84 2017 Survey/reported WHO/UNICEF
92 2020 Survey/reported WHO/UNICEF
93 2021 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

National
Download
Value (%) Year Type Source
95 2017 Survey/reported WHO Immunization Data portal
Infants
Download
Value (%) Year Type Source
95 2019 Survey/reported WHO/UNICEF
94 2020 Survey/reported WHO/UNICEF
96 2021 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Proportion of diagnosed HBV persons receiving appropriate treatment

National
Download
Value (%) Year Type Source
25 2021 Modelled Communication with Egyptian National Liver Institute

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
National prevalence survey within the last 5 years
Not Adopted
Estimates of economic burden
Not Adopted
System for monitoring testing and treatment
Adopted
HepB birth dose policy
Yes
Year of birth dose introduction
2015
Recommendations for HBV testing of pregnant women
Adopted
Eligible for HBV generic medicines
Licensed point-of-care PCR testing to detect HBV
Adopted
HBV testing policy
Risk-based
No patient co-pays for HBsAg testing
Adopted
National treatment guidelines exist
Adopted
Simplified care: Simplified treatment and monitoring algorithm for primary care providers
Not Adopted
Simplified care: No treatment co-pays
Adopted
Adult HBV vaccination policy for high-risk populations
Partially Adopted
Public budget line for testing and treatment
Adopted
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2020
National prevalence survey within the last 5 years
Not Adopted
Estimates of economic burden
Adopted
System for monitoring testing and treatment
Adopted
Recommendations for HCV testing of pregnant women
Adopted
Registration of originator HCV DAAs
Adopted
Eligible for HCV generic medicines
Registration of generic HCV DAAs
Adopted
Licensed point-of-care PCR testing to detect HCV
Adopted
HCV testing policy
Universal
No patient co-pays for anti-HCV testing
Adopted
National treatment guidelines exist
Simplified care: Less than 2 clinic visits during treatment
Adopted
Simplified care: Non-specialists can prescribe treatment
Adopted
Simplified care: No treatment co-pays
Adopted
No fibrosis restrictions
Adopted
National policy for harm reduction for persons who inject drugs
Partially Adopted
National policy for syringe exchange in federal prisons
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Some (11-30%)
Public budget line for testing and treatment
Adopted

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
6 2015 Survey/reported Egypt Ministry of Health et al, 2015
7.3 2013 Modelled Waked et al, 2013
8 2008 Survey/reported El-Zanaty F and Way A, 2008
15 1999 Survey/reported Abdel-Aziz F et al, 2000
0.4 2019 Modelled Communication with Prof Imam Waked, National Liver Institue, Egyptian National Committee for Viral Hepatitis
6.3 (4.50 - 6.70) 2015 Modelled Blach et al, 2017
10 (7 - 12.20) 2014 Survey/reported Gower et al, 2014
2.38 (1.74 - 3.22) 2019 Modelled IHME, GBD 2019 (accessed 2022)
3.35 (2.65 - 4.25) 2018 Modelled IHME, GBD 2019 (accessed 2022)
4.02 (3.21 - 4.99) 2017 Modelled IHME, GBD 2019 (accessed 2022)
4.41 (3.56 - 5.41) 2016 Modelled IHME, GBD 2019 (accessed 2022)
4.71 (3.84 - 5.74) 2015 Modelled IHME, GBD 2019 (accessed 2022)
5.03 (4.15 - 6.02) 2014 Modelled IHME, GBD 2019 (accessed 2022)
5.37 (4.47 - 6.37) 2013 Modelled IHME, GBD 2019 (accessed 2022)
5.67 (4.75 - 6.70) 2012 Modelled IHME, GBD 2019 (accessed 2022)
5.91 (4.97 - 6.95) 2011 Modelled IHME, GBD 2019 (accessed 2022)
6.03 (5.06 - 7.12) 2010 Modelled IHME, GBD 2019 (accessed 2022)
6.08 (5.14 - 7.13) 2009 Modelled IHME, GBD 2019 (accessed 2022)
6.14 (5.22 - 7.19) 2008 Modelled IHME, GBD 2019 (accessed 2022)
6.18 (5.22 - 7.23) 2007 Modelled IHME, GBD 2019 (accessed 2022)
6.19 (5.20 - 7.27) 2006 Modelled IHME, GBD 2019 (accessed 2022)
6.15 (5.16 - 7.29) 2005 Modelled IHME, GBD 2019 (accessed 2022)
6.02 (5.05 - 7.15) 2004 Modelled IHME, GBD 2019 (accessed 2022)
5.81 (4.87 - 6.94) 2003 Modelled IHME, GBD 2019 (accessed 2022)
5.6 (4.67 - 6.74) 2002 Modelled IHME, GBD 2019 (accessed 2022)
5.43 (4.51 - 6.56) 2001 Modelled IHME, GBD 2019 (accessed 2022)
5.35 (4.42 - 6.49) 2000 Modelled IHME, GBD 2019 (accessed 2022)
5.34 (4.43 - 6.49) 1999 Modelled IHME, GBD 2019 (accessed 2022)
5.36 (4.45 - 6.49) 1998 Modelled IHME, GBD 2019 (accessed 2022)
5.37 (4.46 - 6.52) 1997 Modelled IHME, GBD 2019 (accessed 2022)
5.4 (4.47 - 6.57) 1996 Modelled IHME, GBD 2019 (accessed 2022)
5.42 (4.47 - 6.64) 1995 Modelled IHME, GBD 2019 (accessed 2022)
5.46 (4.51 - 6.67) 1994 Modelled IHME, GBD 2019 (accessed 2022)
5.53 (4.57 - 6.76) 1993 Modelled IHME, GBD 2019 (accessed 2022)
5.62 (4.63 - 6.89) 1992 Modelled IHME, GBD 2019 (accessed 2022)
5.73 (4.71 - 7.05) 1991 Modelled IHME, GBD 2019 (accessed 2022)
5.85 (4.79 - 7.25) 1990 Modelled IHME, GBD 2019 (accessed 2022)
1.98 (1.28 - 2.86) 2019 Modelled IHME, GBD 2019 (accessed 2020)
Showing out of
Show more
Women of childbearing age (15–49 years)
Download
Value (%) Year Type Source
1.38 (0.99 - 1.49) 2019 Modelled Dugan et al., 2021
Technical notes

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
6.3 2015 Survey/reported Egypt Ministry of Health et al, 2015
12 2008 Survey/reported El-Zanaty F and Way A, 2008
23.7 1999 Survey/reported Abdel-Aziz F et al, 2000
14.7 (13.90 - 15.50) 2008 Survey/reported Guerra et al, 2012
14.7 (10.30 - 18) 2014 Survey/reported Gower et al, 2014
Showing out of
Show more
People who inject drugs (PWID)
Download
Value (%) Year Type Source
49.4 (35.80 - 63) 1995 Modelled Nelson P et al, 2011
Technical notes

Number of people living with chronic HCV (RNA+/cAg)

National
Download
Value Year Type Source
5,625,000 (4,007,000 - 6,044,000) 2015 Modelled Blach et al, 2017
450,000 2021 Modelled Communication with Egyptian National Liver Institute
3,138,890 (2,569,950 - 3,901,850) 1990 Modelled IHME, GBD 2019 (accessed 2022)
3,137,290 (2,576,330 - 3,860,920) 1991 Modelled IHME, GBD 2019 (accessed 2022)
3,139,450 (2,581,510 - 3,856,420) 1992 Modelled IHME, GBD 2019 (accessed 2022)
3,149,370 (2,598,680 - 3,850,940) 1993 Modelled IHME, GBD 2019 (accessed 2022)
3,169,650 (2,621,870 - 3,847,390) 1994 Modelled IHME, GBD 2019 (accessed 2022)
3,205,740 (2,642,500 - 3,897,580) 1995 Modelled IHME, GBD 2019 (accessed 2022)
3,250,710 (2,681,640 - 3,947,630) 1996 Modelled IHME, GBD 2019 (accessed 2022)
3,296,300 (2,732,420 - 4,005,230) 1997 Modelled IHME, GBD 2019 (accessed 2022)
3,346,880 (2,778,990 - 4,052,170) 1998 Modelled IHME, GBD 2019 (accessed 2022)
3,405,490 (2,826,800 - 4,124,430) 1999 Modelled IHME, GBD 2019 (accessed 2022)
3,477,330 (2,871,650 - 4,226,570) 2000 Modelled IHME, GBD 2019 (accessed 2022)
3,602,570 (2,989,250 - 4,365,200) 2001 Modelled IHME, GBD 2019 (accessed 2022)
3,797,530 (3,162,110 - 4,580,810) 2002 Modelled IHME, GBD 2019 (accessed 2022)
4,028,520 (3,367,610 - 4,823,640) 2003 Modelled IHME, GBD 2019 (accessed 2022)
4,257,310 (3,571,530 - 5,064,580) 2004 Modelled IHME, GBD 2019 (accessed 2022)
4,443,230 (3,731,790 - 5,267,590) 2005 Modelled IHME, GBD 2019 (accessed 2022)
4,569,020 (3,838,300 - 5,373,070) 2006 Modelled IHME, GBD 2019 (accessed 2022)
4,657,210 (3,939,440 - 5,462,500) 2007 Modelled IHME, GBD 2019 (accessed 2022)
4,721,010 (3,987,880 - 5,524,300) 2008 Modelled IHME, GBD 2019 (accessed 2022)
4,772,680 (4,037,360 - 5,596,160) 2009 Modelled IHME, GBD 2019 (accessed 2022)
4,826,930 (4,058,190 - 5,707,110) 2010 Modelled IHME, GBD 2019 (accessed 2022)
4,827,170 (4,067,810 - 5,685,030) 2011 Modelled IHME, GBD 2019 (accessed 2022)
4,725,460 (3,962,350 - 5,587,440) 2012 Modelled IHME, GBD 2019 (accessed 2022)
4,554,920 (3,803,030 - 5,406,320) 2013 Modelled IHME, GBD 2019 (accessed 2022)
4,351,040 (3,594,010 - 5,211,520) 2014 Modelled IHME, GBD 2019 (accessed 2022)
4,151,620 (3,376,910 - 5,057,950) 2015 Modelled IHME, GBD 2019 (accessed 2022)
3,951,820 (3,192,990 - 4,844,840) 2016 Modelled IHME, GBD 2019 (accessed 2022)
3,660,010 (2,915,820 - 4,508,990) 2017 Modelled IHME, GBD 2019 (accessed 2022)
3,099,710 (2,449,950 - 3,917,090) 2018 Modelled IHME, GBD 2019 (accessed 2022)
1,963,340 (1,272,010 - 2,833,450) 2019 Modelled IHME, GBD 2019 (accessed 2020)
2,239,660 (1,627,680 - 3,026,590) 2019 Modelled IHME, GBD 2019 (accessed 2022)
Showing out of
Show more
Women of childbearing age (15–49 years)
Download
Value Year Type Source
345,000 (246,000 - 371,000) 2019 Modelled Dugan et al., 2021

Number of new cases of HCV

National
Download
Value Year Type Source
6,000 2021 Modelled Communication with Egyptian National Liver Institute

HCV-related death rate

National
Download
Value (Deaths per 100,000) Year Type Source
35.9 (24.20 - 48.90) 2019 Modelled IHME, GBD 2019 (accessed 2020)
31.56 (25.22 - 38.31) 1990 Modelled IHME, GBD 2019 (accessed 2022)
30.81 (24.74 - 37.41) 1991 Modelled IHME, GBD 2019 (accessed 2022)
29.97 (24.13 - 36.24) 1992 Modelled IHME, GBD 2019 (accessed 2022)
29.77 (24.28 - 35.95) 1994 Modelled IHME, GBD 2019 (accessed 2022)
29.9 (24.36 - 35.80) 1993 Modelled IHME, GBD 2019 (accessed 2022)
29.04 (23.63 - 35.07) 1995 Modelled IHME, GBD 2019 (accessed 2022)
28.69 (23.29 - 34.70) 1996 Modelled IHME, GBD 2019 (accessed 2022)
28.68 (23.23 - 34.62) 1997 Modelled IHME, GBD 2019 (accessed 2022)
28.52 (23.05 - 34.71) 1998 Modelled IHME, GBD 2019 (accessed 2022)
28.39 (23 - 34.35) 1999 Modelled IHME, GBD 2019 (accessed 2022)
27.73 (22.48 - 33.65) 2000 Modelled IHME, GBD 2019 (accessed 2022)
29.04 (23.48 - 35.31) 2001 Modelled IHME, GBD 2019 (accessed 2022)
30.51 (24.65 - 37.36) 2002 Modelled IHME, GBD 2019 (accessed 2022)
32.35 (25.84 - 39.82) 2003 Modelled IHME, GBD 2019 (accessed 2022)
33.14 (26.53 - 40.86) 2004 Modelled IHME, GBD 2019 (accessed 2022)
33.04 (26.40 - 40.55) 2006 Modelled IHME, GBD 2019 (accessed 2022)
33.08 (26.52 - 40.33) 2005 Modelled IHME, GBD 2019 (accessed 2022)
32.97 (26.45 - 40.11) 2007 Modelled IHME, GBD 2019 (accessed 2022)
33.49 (26.76 - 40.69) 2008 Modelled IHME, GBD 2019 (accessed 2022)
34.66 (27.42 - 42.26) 2009 Modelled IHME, GBD 2019 (accessed 2022)
34.74 (27.18 - 42.41) 2010 Modelled IHME, GBD 2019 (accessed 2022)
34.91 (27.25 - 42.85) 2011 Modelled IHME, GBD 2019 (accessed 2022)
35.33 (27.27 - 43.31) 2012 Modelled IHME, GBD 2019 (accessed 2022)
34.68 (27.01 - 41.95) 2013 Modelled IHME, GBD 2019 (accessed 2022)
35.01 (27.04 - 42.60) 2014 Modelled IHME, GBD 2019 (accessed 2022)
35.86 (27.03 - 44.49) 2015 Modelled IHME, GBD 2019 (accessed 2022)
35.64 (25.68 - 47.20) 2017 Modelled IHME, GBD 2019 (accessed 2022)
36.03 (26.43 - 46.28) 2016 Modelled IHME, GBD 2019 (accessed 2022)
35.86 (24.24 - 48.95) 2019 Modelled IHME, GBD 2019 (accessed 2022)
35.72 (24.35 - 48.80) 2018 Modelled IHME, GBD 2019 (accessed 2022)
Showing out of
Show more
Technical notes

HCV-related deaths

National
Download
Value Year Type Source
59,475 2016 Modelled WHO
18,000 2019 Modelled Communication with Egyptian National Liver Institute
35,523 (24,016 - 48,494) 2019 Modelled IHME, GBD 2019 (accessed 2022)
35,523 (24,016 - 48,494) 2019 Modelled IHME, GBD 2019 (accessed 2020)
34,829 (23,744 - 47,578) 2018 Modelled IHME, GBD 2019 (accessed 2022)
34,179 (24,621 - 45,262) 2017 Modelled IHME, GBD 2019 (accessed 2022)
33,961 (24,911 - 43,625) 2016 Modelled IHME, GBD 2019 (accessed 2022)
33,198 (25,023 - 41,187) 2015 Modelled IHME, GBD 2019 (accessed 2022)
31,809 (24,572 - 38,708) 2014 Modelled IHME, GBD 2019 (accessed 2022)
30,896 (24,064 - 37,371) 2013 Modelled IHME, GBD 2019 (accessed 2022)
30,852 (23,815 - 37,820) 2012 Modelled IHME, GBD 2019 (accessed 2022)
29,860 (23,306 - 36,658) 2011 Modelled IHME, GBD 2019 (accessed 2022)
29,102 (22,774 - 35,531) 2010 Modelled IHME, GBD 2019 (accessed 2022)
28,433 (22,494 - 34,664) 2009 Modelled IHME, GBD 2019 (accessed 2022)
26,886 (21,488 - 32,667) 2008 Modelled IHME, GBD 2019 (accessed 2022)
25,907 (20,781 - 31,513) 2007 Modelled IHME, GBD 2019 (accessed 2022)
25,405 (20,298 - 31,182) 2006 Modelled IHME, GBD 2019 (accessed 2022)
24,895 (19,962 - 30,349) 2005 Modelled IHME, GBD 2019 (accessed 2022)
24,410 (19,546 - 30,097) 2004 Modelled IHME, GBD 2019 (accessed 2022)
23,333 (18,636 - 28,717) 2003 Modelled IHME, GBD 2019 (accessed 2022)
21,543 (17,403 - 26,380) 2002 Modelled IHME, GBD 2019 (accessed 2022)
20,078 (16,233 - 24,415) 2001 Modelled IHME, GBD 2019 (accessed 2022)
18,770 (15,215 - 22,781) 2000 Modelled IHME, GBD 2019 (accessed 2022)
18,826 (15,250 - 22,771) 1999 Modelled IHME, GBD 2019 (accessed 2022)
18,528 (14,973 - 22,548) 1998 Modelled IHME, GBD 2019 (accessed 2022)
18,262 (14,790 - 22,048) 1997 Modelled IHME, GBD 2019 (accessed 2022)
17,921 (14,546 - 21,672) 1996 Modelled IHME, GBD 2019 (accessed 2022)
17,795 (14,481 - 21,490) 1995 Modelled IHME, GBD 2019 (accessed 2022)
17,910 (14,605 - 21,622) 1994 Modelled IHME, GBD 2019 (accessed 2022)
17,650 (14,381 - 21,137) 1993 Modelled IHME, GBD 2019 (accessed 2022)
17,359 (13,980 - 20,991) 1992 Modelled IHME, GBD 2019 (accessed 2022)
17,505 (14,055 - 21,256) 1991 Modelled IHME, GBD 2019 (accessed 2022)
17,577 (14,048 - 21,337) 1990 Modelled IHME, GBD 2019 (accessed 2022)
Showing out of
Show more
Technical notes

Percent of cases of hepatocellular carcinoma attributable to HCV

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
76 (59 - 92) 1992 Modelled IHME, GBD 2019 (accessed 2022)
72 (54 - 90) 1990 Modelled IHME, GBD 2019 (accessed 2022)
75 (57 - 93) 1991 Modelled IHME, GBD 2019 (accessed 2022)
82 (67 - 98) 1995 Modelled IHME, GBD 2019 (accessed 2022)
77 (62 - 93) 1993 Modelled IHME, GBD 2019 (accessed 2022)
79 (64 - 94) 1994 Modelled IHME, GBD 2019 (accessed 2022)
86 (70 - 102) 1996 Modelled IHME, GBD 2019 (accessed 2022)
92 (76 - 109) 1999 Modelled IHME, GBD 2019 (accessed 2022)
88 (72 - 104) 1997 Modelled IHME, GBD 2019 (accessed 2022)
90 (73 - 107) 1998 Modelled IHME, GBD 2019 (accessed 2022)
96 (79 - 112) 2000 Modelled IHME, GBD 2019 (accessed 2022)
102 (84 - 119) 2001 Modelled IHME, GBD 2019 (accessed 2022)
107 (88 - 125) 2002 Modelled IHME, GBD 2019 (accessed 2022)
117 (97 - 137) 2004 Modelled IHME, GBD 2019 (accessed 2022)
111 (92 - 131) 2003 Modelled IHME, GBD 2019 (accessed 2022)
129 (107 - 153) 2006 Modelled IHME, GBD 2019 (accessed 2022)
122 (101 - 143) 2005 Modelled IHME, GBD 2019 (accessed 2022)
143 (118 - 168) 2008 Modelled IHME, GBD 2019 (accessed 2022)
137 (113 - 161) 2007 Modelled IHME, GBD 2019 (accessed 2022)
158 (129 - 187) 2009 Modelled IHME, GBD 2019 (accessed 2022)
158 (128 - 191) 2010 Modelled IHME, GBD 2019 (accessed 2022)
160 (128 - 197) 2011 Modelled IHME, GBD 2019 (accessed 2022)
159 (128 - 197) 2013 Modelled IHME, GBD 2019 (accessed 2022)
159 (127 - 198) 2012 Modelled IHME, GBD 2019 (accessed 2022)
160 (126 - 200) 2014 Modelled IHME, GBD 2019 (accessed 2022)
156 (120 - 198) 2015 Modelled IHME, GBD 2019 (accessed 2022)
156 (119 - 204) 2016 Modelled IHME, GBD 2019 (accessed 2022)
156 (118 - 204) 2017 Modelled IHME, GBD 2019 (accessed 2022)
155 (115 - 206) 2018 Modelled IHME, GBD 2019 (accessed 2022)
154 (114 - 206) 2019 Modelled IHME, GBD 2019 (accessed 2022)
63 (54 - 71) 2019 Modelled IHME, GBD 2019 (accessed 2020)
Showing out of
Show more
Technical notes

Number of persons treated for HCV

National
Download
Value Year Type Source
1,600,000 2020 Survey/reported Communication with Prof Waked, 2020
1,600,000 2020 Survey/reported Communication with Professor Imam Waked, Egyptian National Liver Institute
Showing out of
Show more
Ages 15-18
Download
Value Year Type Source
12,000 2020 Survey/reported Communication with Prof Waked, 2020
Technical notes

Cumulative number of persons treated for HCV

National
Download
Value Year Type Source
30,000 2014 Survey/reported WHO, 2021
100,000 2015 Survey/reported WHO, 2021
700,000 2016 Survey/reported WHO, 2021
2,236,670 2018 Survey/reported WHO, 2021
4,000,000 2020 Survey/reported Egypt Today Staff
Showing out of
Show more

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016

Proportion of persons living with HCV diagnosed

12 years of age and older
Download
Value (%) Year Type Source
96 2021 Modelled Communication with Egyptian National Liver Institute

Price of HCV cure (Cheapest price in private sector for 3 months of DAAs)

National
Download
Value (US $) Year Type Source
18 2019 Survey/reported WHO, 2021

Price of HCV cure (Average price in public sector for 3 months of DAAs)

National
Download
Value (US $) Year Type Source
33 2019 Survey/reported WHO, 2021

Price of HCV cure (Cheapest price in public sector for 3 months of DAAs)

National
Download
Value (US $) Year Type Source
18 2019 Survey/reported WHO, 2021

Price of HCV cure (Average price in private sector for 3 months of DAAs)

National
Download
Value (US $) Year Type Source
54 2019 Survey/reported WHO, 2021
HBV National Action Plan
HBV elimination goal
National prevalence survey within the last 5 years
Not Adopted
Estimates of economic burden
Not Adopted
System for monitoring testing and treatment
Adopted
HepB birth dose policy
Yes
Year of birth dose introduction
2015
Recommendations for HBV testing of pregnant women
Adopted
Eligible for HBV generic medicines
Licensed point-of-care PCR testing to detect HBV
Adopted
HBV testing policy
Risk-based
No patient co-pays for HBsAg testing
Adopted
National treatment guidelines exist
Adopted
Simplified care: Simplified treatment and monitoring algorithm for primary care providers
Not Adopted
Simplified care: No treatment co-pays
Adopted
Adult HBV vaccination policy for high-risk populations
Partially Adopted
Public budget line for testing and treatment
Adopted
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2020
National prevalence survey within the last 5 years
Not Adopted
Estimates of economic burden
Adopted
System for monitoring testing and treatment
Adopted
Recommendations for HCV testing of pregnant women
Adopted
Registration of originator HCV DAAs
Adopted
Eligible for HCV generic medicines
Registration of generic HCV DAAs
Adopted
Licensed point-of-care PCR testing to detect HCV
Adopted
HCV testing policy
Universal
No patient co-pays for anti-HCV testing
Adopted
National treatment guidelines exist
Simplified care: Less than 2 clinic visits during treatment
Adopted
Simplified care: Non-specialists can prescribe treatment
Adopted
Simplified care: No treatment co-pays
Adopted
No fibrosis restrictions
Adopted
National policy for harm reduction for persons who inject drugs
Partially Adopted
National policy for syringe exchange in federal prisons
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Some (11-30%)
Public budget line for testing and treatment
Adopted

Overview

HBV elimination goal
HCV elimination goal
Year of goal
2020

Hepatitis related deaths (national)

Modelled

HBV
19,190
2019
(11,665 - 28,385)
IHME, GBD 2019 (accessed 2022)

Survey/surveillance

No data available
HBV chart

Modelled

HCV
35,523
2019
(24,016 - 48,494)
IHME, GBD 2019 (accessed 2022)

Survey/surveillance

No data available
HCV chart

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
93 (%)
2021
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines

Resources